New Delhi, Oct. 29 -- Eli Lilly said on Wednesday its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk's Ozempic on blood sugar control and delivered more than double the weight loss in a diabetes study.

Retatrutide is widely expected to fuel Lilly's next wave of growth following the success of its Zepbound and Mounjaro.

In previous studies, the drug has already shown a bariatric-surgery level of weight loss in patients with obesity, likely positioning it to be the most powerful drug in the booming market.

Commonly nicknamed "triple-G", the once-weekly retatrutide activates GLP-1, GIP and glucagon hormone receptors.

Triple-G drugs are expected to deliver greater weight loss than earlier generations by ...